Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 18/20 | 0.80 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1403390 | 0.98 | HSD11B1 (0.80) | HSD11B1TP53MAPTTHRB | |
| SCHEMBL1403321 | 0.89 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL1403053 | 0.87 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL1402957 | 0.85 | HSD11B1 (0.81) | HSD11B1 | |
| SCHEMBL1402491 | 0.84 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL1403088 | 0.83 | HSD11B1 (0.81) | HSD11B1 | |
| SCHEMBL1403292 | 0.83 | HSD11B1 (0.81) | HSD11B1 | |
| SCHEMBL1192385 | 0.83 | HSD11B1 (0.81) | HSD11B1 | |
| SCHEMBL1402782 | 0.83 | HSD11B1 (0.83) | HSD11B1 | |
| SCHEMBL1403075 | 0.83 | HSD11B1 (0.81) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344016-B2 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| US-8344016-B2 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| US-8344016-B2 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| US-20110224273-A1 | Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224273-A1 | Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224273-A1 | Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| EP-2292228-A1 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | AstraZeneca AB (Publ) (SE) | 2011-03-09 | — | — | EP | disclosed |
| EP-2292228-A1 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | AstraZeneca AB (Publ) (SE) | 2011-03-09 | — | — | EP | disclosed |
| US-7816391-B2 | 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; hydroxysteroid reductase inhibitors; hydrolysis; metabolic syndromes | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-7816391-B2 | 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; hydroxysteroid reductase inhibitors; hydrolysis; metabolic syndromes | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-7816391-B2 | 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; hydroxysteroid reductase inhibitors; hydrolysis; metabolic syndromes | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-20090221663-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221663-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221663-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| WO-2008099145-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224273-A1 | Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885TP53 3666/4885MAPT 2884/4885 |
| US-20090221663-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885TP53 3666/4885MAPT 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.